COMPASS Pathways plc (CMPS)
After hours:
| Previous Close | 10.79 |
| Open | 10.64 |
| Bid | 10.00 x 1400 |
| Ask | 10.45 x 800 |
| Day's Range | 10.20 - 10.95 |
| 52 Week Range | 6.54 - 28.98 |
| Volume | |
| Avg. Volume | 316,631 |
| Market Cap | 456.935M |
| Beta (5Y Monthly) | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings Date | Nov 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.27 |
- Motley Fool
3 Big Trends Shaking Up Psychedelic Stocks
Just as the idea of using psychedelic medicines to treat mental illnesses is gaining traction in society, psychedelics-focused biotech companies are becoming legitimate and lucrative investments that could help your portfolio in the future. Before you can appreciate which psychedelics players are worth investing in, you'll need to get a feeling for where the industry is going and how it's changing. As inflation surges in the U.S., the Federal Reserve is trying to stop it by hiking the federal funds rate, which ultimately determines how much interest companies need to pay when they take out fresh debt.
- GlobeNewswire
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be acc
- Reuters
REFILE-Magic mushroom compound shows promise as depression treatment in key study
The main psychoactive ingredient found in magic mushrooms can significantly reduce symptoms of difficult-to-treat depression, data from the largest clinical trial ever to test the keenly-watched compound has found. The mid-stage study, conducted by the London-based and Nasdaq-listed COMPASS Pathways, involved 233 patients with so-called treatment-resistant depression who have failed to benefit from at least two antidepressants. COMPASS' compound is believed to target the bits of the brain intimately involved with processing emotion, said James Rucker, consultant psychiatrist and senior clinical lecturer at King’s College London, who was involved in the study.
